Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted 17 January, 2011 and appeared in  Safety and Error PreventionMedicationType 2 DiabetesType 1 DiabetesIssue 557

Why Don't People Take Their Insulin as Prescribed?

Risk factors differed between Type 1 and Type 2 diabetic patients, with diet nonadherence more prominent in Type 1 diabetes and….

Advertisement

The purpose of this study was to assess factors associated with patient frequency of intentionally skipping insulin injections, according to researcher Mark Peyrot, PhD. 

Data were obtained through an internet survey of 502 U.S. adults self-identified as taking insulin by injection to treat Type 1 or Type 2 diabetes. Multiple regression analysis assessed independent associations of various demographic, disease, and injection-specific factors with insulin omission.

Intentional insulin omission was reported by more than half of respondents; regular omission was reported by 20%. Risk factors differed between Type 1 and Type 2 diabetic patients, with diet nonadherence more prominent in Type 1 diabetes and age, education, income, pain, and embarrassment more prominent in Type 2 diabetes.   It is not surprising that non-compliance in Type 1 diabetes patients was associated with poor eating habits. The researchers found that younger age, lower income, and embarrassment were the most important factors for poor compliance in people with Type 2 diabetes. 

Whereas most patients did not report regular intentional omission of insulin injections, a substantial number did. The findings suggest that it is important to identify patients who intentionally omit insulin and be aware of the potential risk factors identified here. For patients who report injection-related problems (interference with daily activities, injection pain, and embarrassment), providers should consider recommending strategies and tools for addressing these problems to increase adherence to prescribed insulin regimens. This could improve clinical outcomes. Although the results address the needed educational intervention, especially when it comes to embarrassment, pain, and interference with activities, it also points to the fact that healthcare teams need to talk with patients before this becomes a common practice, rather than a single occurrence.

Diabetes Care, Feb. 2011

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 17 January, 2011 and appeared in  Safety and Error PreventionMedicationType 2 DiabetesType 1 DiabetesIssue 557

Past five issues: Issue 744 | Diabetes Clinical Mastery Series Issue 203 | Issue 743 | Diabetes Clinical Mastery Series Issue 202 | SGLT-2 Inhibitors Special Edition August 2014 |

2014 Most Popular Articles:

Low-carb Diet Recommended for Type 1 and 2 Diabetes Patients
Posted August 01, 2014
New Combination of Diabetes Drugs Have Synergistic Effect
Posted August 08, 2014
FDA Approves J&J's Invokamet Combo (SGLT-2 + Metformin)
Posted August 15, 2014
New Encapsulated Beta-Cell Replacement Therapy for Type 1 Diabetes
Posted August 08, 2014
Diabetic Neuropathy Improved with Vegan Diet
Posted August 22, 2014
During Prolonged Low-Intensity Exercise, Caffeine Alters Blood Glucose
Posted August 15, 2014
SGLT2 Inhibitor Empagliflozin Wins FDA OK
Posted August 08, 2014
CDC: 40% of American Adults Will Develop Diabetes
Posted August 22, 2014
HbA1c Increases with Age
Posted August 01, 2014
New Way to Regenerate Beta Cells in Type 1 Diabetes Patients
Posted August 08, 2014


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Bernstein | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
When Afrezza is available, will you prescribe it immediately or wait until it has been on the market for a while?
CME/CE of the Week
Preventing Diabetes
Ronald Tamler, PhD, MD, MBA

Category: General Diabetes
CE Credits: .75



Search Articles On Diabetes In Control